Cresco Labs (OTCMKTS:CRLBF – Get Free Report) and TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, analyst recommendations and dividends.
Volatility and Risk
Cresco Labs has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500. Comparatively, TriSalus Life Sciences has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500.
Profitability
This table compares Cresco Labs and TriSalus Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cresco Labs | -7.79% | -14.25% | -3.90% |
| TriSalus Life Sciences | -98.45% | N/A | -111.88% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cresco Labs | 0 | 2 | 0 | 0 | 2.00 |
| TriSalus Life Sciences | 1 | 0 | 4 | 0 | 2.60 |
TriSalus Life Sciences has a consensus price target of $10.50, indicating a potential upside of 126.78%. Given TriSalus Life Sciences’ stronger consensus rating and higher possible upside, analysts clearly believe TriSalus Life Sciences is more favorable than Cresco Labs.
Earnings and Valuation
This table compares Cresco Labs and TriSalus Life Sciences”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cresco Labs | $724.34 million | 0.41 | -$74.44 million | ($0.15) | -5.54 |
| TriSalus Life Sciences | $29.43 million | 7.85 | -$30.05 million | ($2.02) | -2.29 |
TriSalus Life Sciences has lower revenue, but higher earnings than Cresco Labs. Cresco Labs is trading at a lower price-to-earnings ratio than TriSalus Life Sciences, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
0.1% of Cresco Labs shares are held by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are held by institutional investors. 27.5% of TriSalus Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
TriSalus Life Sciences beats Cresco Labs on 9 of the 14 factors compared between the two stocks.
About Cresco Labs
Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co. brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand. The company also offers cannabis flowers under the FloraCal brand; and chocolate and toffee confections and fruit-forward gummies under the Mindy's Edibles brand, as well as licenses the Kiva brand, which produces cannabis infused edibles, including chocolate confections, gummies, mints, and tarts. In addition, the company offers cannabis-infused edibles under the Sunnyside brand. The company was incorporated in 1990 and is headquartered in Chicago, Illinois.
About TriSalus Life Sciences
TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.
Receive News & Ratings for Cresco Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cresco Labs and related companies with MarketBeat.com's FREE daily email newsletter.
